Clinical Insight | CED Clinic

On April 23, 2026, the U.S. Department of Justice moved state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III of the Controlled Substances Act. It is the first formal federal acknowledgment in 55 years that cannabis has accepted medical use. The order changes research access, tax law, and the prescribing conversation — though it stops well short of legalization, and adult-use cannabis remains Schedule I.

For over half a century, physicians who wanted to study cannabis formally faced a federal wall that classified it alongside heroin, with no accepted medical use and no pathway for standard clinical investigation. That wall has a door in it now. The April 23 order does not tear the wall down, but it does open that door specifically for state-licensed medical programs — and that shift, small as it may seem in the headlines, changes the research trajectory in ways that will eventually reach every patient I see.

Acting Attorney General Todd Blanche signed the DOJ order on April 23, 2026, pursuant to President Trump’s December 18, 2025 Executive Order directing agencies to expedite cannabis rescheduling. The order takes immediate effect — not through the usual notice-and-comment rulemaking process, but via the treaty-compliance pathway under 21 U.S.C. §811(d)(1), the same mechanism DEA used in 2018 to schedule certain FDA-approved CBD products. Two categories moved to Schedule III: FDA-approved products containing cannabis (currently including Epidiolex) and cannabis products regulated by a qualifying state medical marijuana license. All other cannabis — every recreational product in adult-use states — remains Schedule I unless and until a broader rescheduling follows the DEA administrative hearing scheduled to begin June 29, 2026.

The material downstream effects are three. First, Section 280E of the Internal Revenue Code no longer applies to qualifying state-licensed medical operators, potentially dropping effective tax rates from near 70 percent to 20 to 30 percent — a financial shift the Cannabis Regulators Association describes as the most immediate practical impact for medical operators. Second, research access improves: Schedule III substances face less restrictive DEA registration requirements than Schedule I, meaning investigators can access cannabis for study through pathways that were previously closed or severely bottlenecked. Third, the order formally acknowledges, for the first time in the 55-year history of the Controlled Substances Act, that cannabis has an accepted medical use — a statement with real downstream consequences for insurance coverage conversations and the long-term normalization of cannabis medicine within clinical practice.

The Federal Acknowledgment That Cannabis Has Medical Value Is Not Nothing

Patients have been asking me about this order since it was announced. Some are thrilled. Some are skeptical. A few came in certain that cannabis just got legalized. None of those reactions is quite right, and I want to work through what I actually think about this, because the reflexive responses in both directions are getting in the way of the real story.

Let me start with what this is. The DOJ order moved state-licensed medical cannabis from Schedule I to Schedule III. Schedule I means no accepted medical use, high abuse potential, and essentially no lawful path for clinical research. Schedule III means accepted medical use, moderate to low physical dependence potential. Ketamine is Schedule III. Anabolic steroids are Schedule III. Tylenol with codeine is Schedule III. The federal government just put medical cannabis in that company, officially, for the first time in 55 years. That is a meaningful statement, not a minor administrative footnote.

What it does not mean: legalization. Cannabis outside of FDA approval or a qualifying state medical license stays at Schedule I. Every recreational product in Massachusetts, Colorado, California, and the 37-plus other adult-use jurisdictions is in the same legal position this morning as it was a month ago. And even for medical cannabis, the order does not create a federal regulatory framework for dosing, potency standards, labeling consistency, or clinical protocols. Those gaps are not trivial. They are exactly where the research needs to fill in.

Here is why the research piece matters most to me clinically. I have been practicing cannabis medicine for over two decades, working with tens of thousands of patients across a range of conditions. The single greatest obstacle to giving patients good clinical guidance has not been stigma. It has not been product availability. It has been the absence of the kind of rigorous, large-scale, well-controlled clinical trials that we take for granted in every other corner of medicine. That absence was not accidental. Schedule I classification created structural barriers to doing the research, barriers that affected everything from DEA registration requirements to institutional review board approvals to the ability of researchers to source study-grade material. Those barriers are now lower, specifically for medical cannabis.

The treaty-compliance pathway used here is worth understanding, because it explains why this happened so fast. Standard rulemaking under the Controlled Substances Act requires notice, public comment, administrative hearings — a process that took years under the Biden administration and ultimately stalled. The treaty pathway (21 U.S.C. §811(d)(1)) allows the DEA to act immediately when consistency with U.S. treaty obligations is invoked. This is the same mechanism used in 2018 to reschedule FDA-approved CBD. Critics will argue the pathway was stretched here; the order includes a severability clause precisely because the DOJ anticipates legal challenges. Whether those challenges succeed will shape how permanent this shift turns out to be. In the meantime, the order has effect.

For patients at CED Clinic, especially those in Massachusetts where the medical program operates under state law, the practical near-term implications are modest but real. The prescribing relationship itself does not change — physicians are still recommending rather than prescribing cannabis under state certification frameworks. What changes is the downstream conversation: federal acknowledgment of medical use strengthens the case for insurance coverage, which remains essentially absent; it reduces some legal ambiguity that has hung over the banking and business side of the medical programs patients rely on; and it opens a more viable path for the kind of prospective trials that could, within years, give us the evidence base the field currently lacks.

I want to be clear about the June 29 hearing, because it is the next critical date. That DEA administrative hearing will determine whether all cannabis, including adult-use, moves to Schedule III through full rulemaking. The outcome is not certain. The process could take months after the hearing concludes. Legal challenges could extend the timeline further. What has been firmly established as of April 28 is the medical carve-out — and that is where the clinical story begins.

A new policy doesn’t change what cannabis does in the body. It changes who gets to study it, who gets to afford it, and how easily patients can discuss it with their physicians without the shadow of federal illegality framing the conversation. Those are not small things. They are, in fact, the conditions under which good medicine eventually becomes possible.

The federal policy arc on cannabis has been slow and interrupted. A 2024 proposed rule from the Biden-era DEA started a rescheduling process that stalled when the sole administrative law judge presiding over it retired in July 2025. The Trump Executive Order of December 2025 restarted the clock. This April order is the first concrete structural outcome. Contextually, prior HHS review in 2023 had already recommended Schedule III placement, citing evidence of accepted medical use — so the scientific rationale for this order was not built from scratch. The legal mechanism differs from full rulemaking, which is why the order could take effect in days rather than years. How the June 29 hearing resolves the broader recreational question will determine whether this moment becomes a floor or a ceiling for federal cannabis reform.

For physicians counseling medical cannabis patients in Massachusetts and other licensed-state programs, the most actionable near-term consideration is documentation. As DEA registration becomes newly available to state-licensed medical entities, the regulatory landscape for medical providers may shift in ways that touch record-keeping, referral patterns, and reimbursement conversations. The 280E tax relief now available to qualifying medical operators also improves the financial stability of dispensary programs that many patients depend on for consistent product access. Talk to your patients now about what they’re using, from where, and under what program — the documentation you build in this period will matter as the regulatory picture clarifies.

This is a regulatory order, not a clinical study. It carries the legal authority of the Department of Justice and DEA under the Controlled Substances Act. The order’s immediate effects on tax law and research access are legally operative; the broader clinical and research implications will materialize over months and years as institutions, investigators, and state programs adapt. The June 29 DEA hearing will produce an evidentiary record that may influence future policy, but it is not a controlled trial and its outcomes will be subject to legal challenge.

The public comment analysis published on CEDclinic.com in late April documented the breadth of stakeholder input during the 2024 proposed-rule comment period — illustrating just how complex and contested the rescheduling conversation has been at every level, from patient advocates to law enforcement to academic researchers. A 2023 systematic review by Caulkins et al. in the journal Drug and Alcohol Dependence found that Schedule I restrictions had measurably constrained the research pipeline, particularly for human clinical trials examining therapeutic outcomes. The current order is the first policy response that directly addresses that constraint for the medical segment.

Parallel policy discussions are underway internationally. Canada’s fully legal and federally regulated cannabis market has produced a growing cohort of post-legalization observational data; the United Kingdom’s rescheduling of medical cannabis in 2018 produced a wave of real-world evidence studies that are still being published. The U.S. now has a framework, however partial, to begin generating comparable data at scale.

The most common misreading circulating in patient communities is that this order legalizes cannabis federally. It does not. Cannabis outside of FDA approval or a qualifying state medical license remains Schedule I. Patients in adult-use states who consume recreational products are in the same federal legal position today as they were before April 23. Federal prosecution of individuals remains an enforcement priority question distinct from the scheduling question — but the scheduling has not changed for recreational use.

A second misreading is that the order resolves the banking problem for all cannabis businesses. It does not. Banking relief under the SAFER Banking Act remains pending in Congress. The 280E relief applies only to state-licensed medical operators; recreational businesses remain fully subject to 280E until broader rescheduling is completed through the June hearing or congressional action.

The April 23 DOJ order is a genuine milestone: the first federal recognition that medical cannabis has accepted medical value. It reduces research barriers, eliminates 280E tax burden for qualifying medical operators, and sets up a June 29 hearing on broader rescheduling. It does not legalize cannabis, does not create insurance coverage, and does not resolve the recreational cannabis question. For patients and clinicians, the key near-term task is informed clarity about what changed and disciplined patience for what comes next.

Does this order mean cannabis is now legal under federal law?

No. The order moves state-licensed medical cannabis to Schedule III — a controlled substance with accepted medical use, but still federally regulated. Cannabis outside of FDA-approved products or a qualifying state medical license remains Schedule I. Federal legalization would require separate congressional action.

I’m a medical cannabis patient in Massachusetts. What changes for me right now?

Your certification and access through the Massachusetts medical program are governed by state law, which has not changed. What may improve over time is the financial stability of the dispensaries you rely on (due to 280E relief), the likelihood of expanded research validating specific uses, and the broader cultural and institutional legitimacy of cannabis medicine in clinical settings.

Will this help with insurance coverage for medical cannabis?

Not immediately. The order does not mandate insurance coverage. However, the formal federal acknowledgment of accepted medical use strengthens the long-term argument for coverage. Insurance coverage conversations in Washington and with individual payers will likely cite this order — but practical reimbursement changes are measured in years, not months.

What happens at the June 29 DEA hearing?

The DEA will hold an administrative hearing to evaluate whether all cannabis — including recreational products — should be moved from Schedule I to Schedule III through full rulemaking. Companies, advocacy groups, law enforcement, and medical organizations can participate by filing notice by May 20 (mail) or May 24 (email). A final rule, if the process runs on schedule, could arrive as early as late 2026, though legal challenges may extend the timeline.

What does this mean for cannabis research?

Schedule III substances face materially less restrictive DEA registration requirements than Schedule I, which had created significant bureaucratic barriers for researchers wanting to study cannabis clinically. This should translate into a more accessible pathway for clinical investigators, though institutions still need to navigate their own IRB processes and funding sources. The pipeline effect will take time to materialize in published literature.

1. U.S. Department of Justice. Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III, Strengthening Medical Research While Maintaining Strict Federal Controls. April 23, 2026. DOJ Press Release
2. Source: https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana
3. Drug Enforcement Administration. Notice of Hearing on Proposed Rulemaking: Schedules of Controlled Substances. Federal Register, April 2026. Hearing to commence June 29, 2026.
4. Foley Hoag LLP. DOJ Immediately Reschedules State-Licensed Medical Cannabis to Schedule III — and Restarts the Clock on Broader Rescheduling. April 23, 2026. Foley Hoag Alert
5. Gibson Dunn. DEA Downschedules State Medical Marijuana to Schedule III; Expedited Hearing Set to Consider Broader Rescheduling. April 2026. Gibson Dunn Analysis
6. Holland & Knight. Cannabis Rescheduling: DOJ Announces Rescheduling of Certain Products. April 2026. Holland & Knight Alert
7. New York Times. The Cannabis Industry’s New Best Friend? President Trump. May 2, 2026. NYT

Have thoughts on this? Share it: